Research chemicalResearch chemicalEntactogenBenzofuran

6-MAPB

Also known as 6-(2-methylaminopropyl)benzofuran

Written by enwyReviewed 4 Aug 20262 sources0 comments

6-MAPB is the N-methyl analogue of 6-APB and a benzofuran counterpart to MDMA. It is a serotonin-norepinephrine-dopamine releaser producing entactogenic effects with a long duration. Human evidence is limited to user reports.

01 Overview

6-MAPB (6-(2-methylaminopropyl)benzofuran) relates to 6-APB as MDMA does to MDA. It shares the long duration characteristic of the 6-position benzofurans and is reported as MDMA-like with a strong entactogenic character.

No controlled clinical data exist. Its risk profile is extrapolated from mechanism, structural similarity to MDMA, and community reports. Serotonergic hazards and cardiovascular strain apply as a class.

02 Mechanism

Releases serotonin, norepinephrine and dopamine; N-methylation shifts the profile toward MDMA-like entactogenesis.

03 Dosing

Tier	Dose	Route	Notes
Light	50–90 mg	Oral	User-reported only.
Common	90–140 mg	Oral	Long duration; redosing compounds cardiovascular load.
Strong	140–180 mg	Oral	Higher serotonergic and thermal risk.

04 Effects

Effect	Magnitude	Evidence
MDMA-like empathyEmotional warmth and openness resembling MDMA.		Anecdotal
Euphoria and sociabilityMood elevation and increased sociability.		Anecdotal
Long durationExtended effect window typical of 6-position benzofurans.	~6-10 h	Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
HyperthermiaOverheating as with other serotonergic releasers.	Severe	Common at higher doses	Observational
Cardiovascular strainTachycardia and hypertension; possible 5-HT2B valvular concern.	Severe	Common	Observational
Serotonin syndromeAutonomic instability, clonus and hyperthermia possible.	Life-threatening	Uncommon; higher with serotonergic drugs	Observational

06 Legal status

United Kingdom

Class B (Misuse of Drugs Act)

Covered by benzofuran controls. · as of Jan 2026

United States

Not federally scheduled

Possible Federal Analogue Act coverage. · as of Jan 2026

07 References

Pharmacology of benzofuran entactogens including 6-MAPBPubMed search

New psychoactive substances - benzofuransEUDA (EMCDDA)

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.